Bartlett J M, Hulme M J, Miller W R
University Department of Surgery, Glasgow Royal Infirmary, UK.
Br J Cancer. 1996 Jun;73(12):1538-44. doi: 10.1038/bjc.1996.290.
A quantitative polymerase chain reaction (PCR) method for determining concentrations of mRNA for the cyclic AMP (cAMP)-binding protein RI alpha, a regulatory subunit of cAMP-dependent protein kinase, was developed using site-directed mutagenic primers and mix-melt PCR. The PCR product for RI alpha mRNA was modified to include an EcoRV restriction site for use as an internal standard. This mutant utilised the same primers as the target mRNA and differed in sequence by only four bases. As only one of these base changes results in a purine/pyrimidine switch the effective change in labelling with [32P]dCTP was less than 0.5%. Reverse transcription of mRNA was performed and quantitative PCR was carried out using fixed levels of mutant RI alpha vs varying amounts of both normal RI alpha sequence of known concentration and unknown samples. Validation of the technique using rigourous quality control established that reverse transcription, determined by incorporation of labelled nucleotides, gave intra- and interassay variations of 16.2 and 9.3% respectively. Using crossover evaluation of cDNA concentrations with cloned RI alpha sequences as controls intra- and interassay variations of 14.3% and 4-8% respectively were obtained. Using compounded errors, the limits of precision for this technique demonstrate that values that are altered by 50% or more represent a true alteration in mRNA levels between samples tested. This value compares favourably to similar values for radioimmunoassays of between 10% and 30% precision. Analysis of a series of patient samples during routine follow-up of treatment demonstrated clear changes in mRNA levels. Using site-directed mutagenesis to establish a quantitative PCR-based assay for expression of mRNA this study demonstrates the potential usefulness and some limitations of quantitative PCR for applications within a clinical biochemistry laboratory. However, based on compounded error, values that vary by less than 50% within assays, and by less than 70% in separate assays could not be clearly separated. Assessment of paired patient samples has demonstrated clear changes in mRNA for the target protein RI alpha. With the use of normal quality control procedures this study has established that the degree of reproducibility of this quantitative PCR technique would allow assessment of mRNA levels for markers of interest in clinical samples in a routine laboratory context.
利用定点诱变引物和混合熔解聚合酶链反应(PCR),开发了一种定量聚合酶链反应(PCR)方法,用于测定环磷酸腺苷(cAMP)结合蛋白RIα(cAMP依赖性蛋白激酶的调节亚基)的mRNA浓度。RIα mRNA的PCR产物经过修饰,包含一个EcoRV限制性酶切位点,用作内标。该突变体使用与靶mRNA相同的引物,序列仅相差四个碱基。由于这些碱基变化中只有一个导致嘌呤/嘧啶转换,因此用[32P]dCTP标记的有效变化小于0.5%。进行mRNA的逆转录,并使用固定水平的突变RIα与已知浓度和未知样品的不同量的正常RIα序列进行定量PCR。使用严格的质量控制对该技术进行验证,结果表明,通过掺入标记核苷酸确定的逆转录,批内和批间变异分别为16.2%和9.3%。以克隆的RIα序列作为对照,对cDNA浓度进行交叉评估,批内和批间变异分别为14.3%和4-8%。使用复合误差,该技术的精密度极限表明,变化50%或更多的值代表所测试样品之间mRNA水平的真实变化。该值与放射免疫分析的类似值(精密度在10%至30%之间)相比具有优势。在治疗的常规随访期间对一系列患者样本进行分析,结果表明mRNA水平有明显变化。本研究利用定点诱变建立了基于定量PCR的mRNA表达检测方法,证明了定量PCR在临床生物化学实验室应用中的潜在实用性和一些局限性。然而,基于复合误差,在分析中变化小于50%、在单独分析中变化小于70%的值无法清晰区分。对配对患者样本的评估表明,靶蛋白RIα的mRNA有明显变化。通过使用正常的质量控制程序,本研究确定,这种定量PCR技术的可重复性程度将允许在常规实验室环境中评估临床样本中感兴趣标记物的mRNA水平。